Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Gritstone bio Inc. | GRANITE-CRC-1L | 1L Microsatellite-Stable Colorectal Cancer (MSS-CRC) | Phase 2/3 | Data Released | Intravenous | Oncology |
| Gritstone bio Inc. | SLATE v1 | Non-small cell lung cancer (NSCLC) | Phase 2 | Trial Completed | oral | Oncology |
| GSK plc American Depositary Shares (Each representing two) | GSK4348413 (GMMA) | Gonorrhea | Phase 2 | Trial Discontinued | Intramuscular | Antibiotic |
| GSK plc American Depositary Shares (Each representing two) | Linerixibat - (GLISTEN) | Primary biliary cholangitis (PBC) | PDUFA | Oral | Gastroenterology | |
| GSK plc American Depositary Shares (Each representing two) | Lete-cel - (IGNYTE-ESO) | Sarcoma | BLA Filing | Data Released | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Belrestotug + dostarlimab + GSK562 - (GSK6097608) | Advanced solid tumors | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Belrestotug (EOS-448/GSK4428859A) - (GALAXIES H&N-202) | PD-L1 positive recurrent / metastatic head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| GSK plc American Depositary Shares (Each representing two) | Belrestotug (EOS-448/GSK4428859A) - (TIG-006 mNSCLC, ENTRÉE) | 1L in advanced or metastatic Non-small cell lung cancer (NSCLC) | Phase 2 | Ongoing | Intravenous | Oncology |
